Skip to main content
SpringerLink
Log in

Class I Antiarrhythmic Drugs

  • Chapter
  • First Online:
Adverse Cutaneous Drug Reactions to Cardiovascular Drugs

  • 906 Accesses

Abstract

Class I antiarrhythmic drugs, also known as sodium channel blockers, are classified into three subgroups such as class Ia (quinidine, procainamide, disopyramide, acecainide), class Ib (lidocaine, mexiletine, tocainide, phenytoin), and class Ic (propafenone, flecainide, encainide, moricizine).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99–105.

    Article  PubMed  Google Scholar 

  2. Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology. 1986;37:968–71.

    CAS  PubMed  Google Scholar 

  3. Sonnhag C, Karlsson E, Hed J. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand. 1979;206:245–51.

    Article  CAS  PubMed  Google Scholar 

  4. List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematol. 1989;82:50–2.

    Article  CAS  PubMed  Google Scholar 

  5. Cohen MG, Kevat S, Prowse MV, Ahern MJ. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med. 1988;108:369–71.

    Article  CAS  PubMed  Google Scholar 

  6. Sukenik S, Horowitz J, Katz A, Henkin J, Buskila D. Quinidine-induced lupus erythematosus-like syndrome: three case reports and a review of the literature. Isr J Med Sci. 1987;23:1232–4.

    CAS  PubMed  Google Scholar 

  7. West SG, McMahon M, Portanova JP. Quinidine-induced lupus erythematosus. Ann Intern Med. 1984;100:840–2.

    Article  CAS  PubMed  Google Scholar 

  8. Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum. 1995;24:315–22.

    Article  CAS  PubMed  Google Scholar 

  9. Guindo J, Rodriguez de la Serna A, Borja J, Oter R, Jane F, Bayes de Luna A. Propafenone and a syndrome of the lupus erythematosus type. Ann Intern Med. 1986;104:589.

    Article  CAS  PubMed  Google Scholar 

  10. Oliphant LD, Goddard M. Tocainide-associated neutropenia and lupus-like syndrome. Chest. 1988;94:427–8.

    Article  CAS  PubMed  Google Scholar 

  11. Gelfand MS, Yunus F, White FL. Bone marrow granulomas, fever, pancytopenia, and lupus-like syndrome due to tocainide. South Med J. 1994;87:839–41.

    Article  CAS  PubMed  Google Scholar 

  12. Couto N, Ferreira M, Reis E. Neutropenia and cutaneous lesions secondary to propafenone. Eur J Dermatol. 2009;19:365–7.

    PubMed  Google Scholar 

  13. Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J. 2003;9:6.

    PubMed  Google Scholar 

  14. Ross S, Ormerod AD, Roberts C, Dwyer C, Herriot R. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol. 2002;27:474–6.

    Article  CAS  PubMed  Google Scholar 

  15. Johansson BW, Stavenow L, Hanson A. Long-term clinical experience with mexiletine. Am Heart J. 1984;107:1099–102.

    Article  CAS  PubMed  Google Scholar 

  16. Armstrong RB, Leach EE, Whitman G, Harber LC, Poh-Fitzpatrick MB. Quinidine photosensitivity. Arch Dermatol. 1985;121:525–8.

    Article  CAS  PubMed  Google Scholar 

  17. Wolf R, Dorfman B, Krakowski A. Quinidine-induced lichenoid and eczematous photodermatitis. Dermatologica. 1987;174:285–9.

    Article  CAS  PubMed  Google Scholar 

  18. Bonnetblanc JM, Bernard P, Catanzano G, Souyri N. Quinidine-induced lichenoid photodermatitis. Ann Dermatol Venereol. 1987;114:957–61.

    CAS  PubMed  Google Scholar 

  19. Gammer S, Gross PR. Photoallergy induced by quinidine. Cutis. 1976;17:72–4.

    CAS  PubMed  Google Scholar 

  20. Schurer NY, Holzle E, Plewig G, Lehmann P. Photosensitivity induced by quinidine sulfate: experimental reproduction of skin lesions. Photodermatol Photoimmunol Photomed. 1992;9:78–82.

    CAS  PubMed  Google Scholar 

  21. Schurer NY, Lehmann P, Plewig G. Quinidine-induced photoallergy. A clinical and experimental study. Hautarzt. 1991;42:158–61.

    CAS  PubMed  Google Scholar 

  22. Marx JL, Eisenstat BA, Gladstein AH. Quinidine photosensitivity. Arch Dermatol. 1983;119:39–43.

    Article  CAS  PubMed  Google Scholar 

  23. Manzi S, Kraus VB, St Clair EW. An unusual photoactivated skin eruption. Quinidine-induced livedo reticularis. Arch Dermatol. 1989;125(417–8):421–2.

    Google Scholar 

  24. Bruce S, Wolf Jr JE. Quinidine-induced photosensitive livedo reticularis-like eruption. J Am Acad Dermatol. 1985;12:332–6.

    Article  CAS  PubMed  Google Scholar 

  25. Bhalla M, Garg G, Thami GP. Photodistribution of rash in phenytoin-induced drug rash with eosinophilia and systemic symptoms. Clin Exp Dermatol. 2011;36:553–4.

    Article  CAS  PubMed  Google Scholar 

  26. Habot B, Rabinovitz C, Friedensohn A, Schlesinger Z, Baumel Y. A severe skin reaction following mexiletene. Harefuah. 1992;123:462, 506.

    CAS  PubMed  Google Scholar 

  27. Dunn JM, Groth PE, DeSimone A. Tocainide: a severe adverse reaction. Drug Intell Clin Pharm. 1988;22:142–5.

    CAS  PubMed  Google Scholar 

  28. Duff HJ, Roden DM, Marney S, Colley DG, Maffucci R, Primm RK, et al. Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. Am Heart J. 1984;107:585–9.

    Google Scholar 

  29. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun AD. Adverse dermatologic effects of cardiovascular drug therapy: part I. Cardiol Rev. 2002;10:230–46.

    Article  PubMed  Google Scholar 

  30. Higa K, Hirata K, Dan K. Mexiletine-induced severe skin eruption, fever, eosinophilia, atypical lymphocytosis, and liver dysfunction. Pain. 1997;73:97–9.

    Article  CAS  PubMed  Google Scholar 

  31. Seino Y, Yamauchi M, Hirai C, Okumura A, Kondo K, Yamamoto M, Okazaki Y. A case of fulminant Type 1 diabetes associated with mexiletine hypersensitivity syndrome. Diabet Med. 2004;21:1156–7.

    Article  CAS  PubMed  Google Scholar 

  32. Morito H, Ogawa K, Kobayashi N, Fukumoto T, Asada H. Drug-induced hypersensitivity syndrome followed by persistent arthritis. J Dermatol. 2012;39:178–9.

    Article  PubMed  Google Scholar 

  33. Pereira de Silva N, Piquioni P, Kochen S, Saidon P. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. Eur J Clin Pharmacol. 2011;67:463–70.

    Article  CAS  PubMed  Google Scholar 

  34. Oelze LL, Pillow MT. Phenytoin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report from the emergency department. J Emerg Med. 2013;44:75–8.

    Article  PubMed  Google Scholar 

  35. Sherertz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid “pulse therapy”. J Am Acad Dermatol. 1985;12(1 Pt 2):178–81.

    Article  CAS  PubMed  Google Scholar 

  36. Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A, Takahashi H, Hashimoto Y, Kimura H, et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J Dermatol. 2005;32:278–81.

    Article  PubMed  Google Scholar 

  37. Yagami A, Yoshikawa T, Asano Y, Koie S, Shiohara T, Matsunaga K. Drug-induced hypersensitivity syndrome due to mexiletine hydrochloride associated with reactivation of human herpesvirus 7. Dermatology. 2006;213:341–4.

    Article  PubMed  Google Scholar 

  38. Lee SP, Kim SH, Kim TH, Sohn JW, Shin DH, Park SS, Yoon HJ. A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. J Korean Med Sci. 2010;25:148–51.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353:2190–4.

    Article  CAS  PubMed  Google Scholar 

  40. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.

    Article  CAS  PubMed  Google Scholar 

  41. Smith DA, Burgdorf WH. Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis. J Am Acad Dermatol. 1984;10:106–9.

    Article  CAS  PubMed  Google Scholar 

  42. Ahmed I, Reichenberg J, Lucas A, Shehan JM. Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature. Int J Dermatol. 2004;43:67–73.

    Article  PubMed  Google Scholar 

  43. Wöhrl S, Loewe R, Pickl WF, Stingl G, Wagner SN. EMPACT syndrome. J Dtsch Dermatol Ges. 2005;3:39–43.

    Article  PubMed  Google Scholar 

  44. Adornato MC. Toxic epidermal necrolysis associated with quinidine administration. N Y State Dent J. 2000;66:38–40.

    CAS  PubMed  Google Scholar 

  45. Arrowsmith JB, Creamer JI, Bosco L. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med. 1987;107:693–6.

    Article  CAS  PubMed  Google Scholar 

  46. Birek C, Main JH. Two cases of oral pigmentation associated with quinidine therapy. Oral Surg Oral Med Oral Pathol. 1988;66:59–61.

    Article  CAS  PubMed  Google Scholar 

  47. Mahler R, Sissons W, Watters K. Pigmentation induced by quinidine therapy. Arch Dermatol. 1986;122:1062–4.

    Article  CAS  PubMed  Google Scholar 

  48. Lee A, Thomson J. Drug-induced skin reactions. In: Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006. p. 125–56.

    Google Scholar 

  49. Kanwar AJ, Jaswal R, Thami GP, Bedi GK. Acquired acromelanosis due to phenytoin. Dermatology. 1997;194:373–4.

    Article  CAS  PubMed  Google Scholar 

  50. Kardaun SH, Scheffer E, Vermeer BJ. Drug-induced pseudolymphomatous skin reactions. Br J Dermatol. 1988;118:545–52.

    Article  CAS  PubMed  Google Scholar 

  51. Sasaki K, Yamamoto T, Kishi M, Yokozeki H, Nishioka K. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol. 2001;11:469–71.

    CAS  PubMed  Google Scholar 

  52. Huang YM, Lee WR, Hu CH, Cheng KL. Propafenone-induced acute generalized exanthematous pustulosis. Int J Dermatol. 2005;44:256–7.

    Article  PubMed  Google Scholar 

  53. Burkhart CG. Quinidine-induced acne. Arch Dermatol. 1981;117:603–4.

    Article  CAS  PubMed  Google Scholar 

  54. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009;93:1161–81.

    Article  CAS  PubMed  Google Scholar 

  55. Grunwald MH, Ben-Dor D, Livni E, Halevy S. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol. 1990;29:559–61.

    Article  CAS  PubMed  Google Scholar 

  56. Sharma VK, Dhar S, Gill AN. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol. 1996;23:530–4.

    CAS  PubMed  Google Scholar 

  57. Garcia JC, Torre F, Sanchez M, Martin JA, Canto G. Fixed drug eruption induced by lidocaine and patch testing. J Investig Allergol Clin Immunol. 1997;7:127–8.

    CAS  PubMed  Google Scholar 

  58. Kawada A, Noguchi H, Hiruma M, Tajima S, Ishibashi A, Marshall J. Fixed drug eruption induced by lidocaine. Contact Dermatitis. 1996;35:375.

    Article  CAS  PubMed  Google Scholar 

  59. Knapp 3rd CF, Cooke ER, Sheehan DJ. Bullous fixed drug eruption caused by flecainide. J Am Acad Dermatol. 2009;60:e3.

    Article  PubMed  Google Scholar 

  60. Almeyda J, Levantine A. Cutaneous reactions to cardiovascular drugs. Br J Dermatol. 1973;88:313–9.

    Article  CAS  PubMed  Google Scholar 

  61. Shalit M, Flugelman MY, Harats N, Galun E, Ackerman Z, Kopolovic J, Eliakim M. Quinidine-induced vasculitis. Arch Intern Med. 1985;145:2051–2.

    Article  CAS  PubMed  Google Scholar 

  62. Aviram A. Henoch-Schonlein syndrome associated with quinidine. JAMA. 1980;243:432–3.

    Article  CAS  PubMed  Google Scholar 

  63. Rosin JM. Vasculitis following procaineamide therapy. Am J Med. 1967;42:625–9.

    Article  CAS  PubMed  Google Scholar 

  64. Knox JP, Welykyj SE, Gradini R, Massa MC. Procainamide-induced urticarial vasculitis. Cutis. 1988;42:469–72.

    CAS  PubMed  Google Scholar 

  65. Jackson C, Phillips PE. Procainamide-induced lupus with vasculitis. Clin Exp Rheumatol. 1986;4:290–2.

    CAS  PubMed  Google Scholar 

  66. Nieminen U, Kekomaki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol. 1992;80:77–82.

    Article  CAS  PubMed  Google Scholar 

  67. Brenner WI, Heslov SF, Deosaransingh M. Fatal quinidine-induced thrombocytopenia following open-heart surgery. Tex Heart Inst J. 1990;17:237–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.

    Google Scholar 

  69. García-Vilanova-Comas A, Fuster-Diana C, Cubells-Parrilla M, Pérez-Ferriols MD, Pérez-Valles A, Roig-Vila JV. Nicolau syndrome after lidocaine injection and cold application: a rare complication of breast core needle biopsy. Int J Dermatol. 2011;50:78–80.

    Article  PubMed  Google Scholar 

  70. Bassan MM, Sheikh-Hamad D. Prevention of lidocaine-infusion phlebitis by heparin and hydrocortisone. Chest. 1983;84:439–41.

    Article  CAS  PubMed  Google Scholar 

  71. Cadenbach A, Rottger K, Muller MK. Purple glove syndrome. Severe soft tissue reaction following phenytoin infusion. Dtsch Med Wochenschr. 1998;123:318–22.

    Article  CAS  PubMed  Google Scholar 

  72. Chokshi R, Openshaw J, Mehta NN, Mohler 3rd E. Purple glove syndrome following intravenous phenytoin administration. Vasc Med. 2007;12:29–31.

    Article  PubMed  Google Scholar 

  73. Ponte CD, Horner P. Suspected procainamide-induced angioedema. Drug Intell Clin Pharm. 1985;19:139–40.

    CAS  PubMed  Google Scholar 

  74. Incorvaia C, Pravettoni C, Riario-Sforza GG. Urticaria-angioedema reaction caused by propafenone. Allergy. 2006;61:269.

    Article  CAS  PubMed  Google Scholar 

  75. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004;15:28–46.

    Article  PubMed  Google Scholar 

  76. Martinez-Selles M, Castillo I, Montenegro P, Martin ML, Almendral J, Sanjurjo M. Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation. Rev Esp Cardiol. 2005;58:745–8.

    Article  PubMed  Google Scholar 

  77. Casetta I, Granieri E, Desidera M, Monetti VC, Tola MR, Paolino E, et al. Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology. 1997;16:296–303.

    Article  CAS  PubMed  Google Scholar 

  78. Perlik F, Kolinova M, Zvarova J, Patzelova V. Phenytoin as a risk factor in gingival hyperplasia. Ther Drug Monit. 1995;17:445–8.

    Article  CAS  PubMed  Google Scholar 

  79. Wittkowsky AK, Reddy R, Bardy GH. Oral mucosal ulceration from disopyramide. Ann Pharmacother. 1995;29:1299–300.

    CAS  PubMed  Google Scholar 

  80. Bellogini GC, Oneglia C. Exfoliative dermatitis caused by quinidine. Description of a clinical case. Minerva Cardioangiol. 1987;35:457–9.

    CAS  PubMed  Google Scholar 

  81. Gouffault J, Pawlotsky Y, Morel H, Bourel M. Erythrodermia of quinidine origin. Sem Hop. 1965;41:1350–3.

    CAS  PubMed  Google Scholar 

  82. Tran D, Kossard S, Shumack S. Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis. Australas J Dermatol. 2003;44:284–6.

    Article  PubMed  Google Scholar 

  83. Acostamadiedo JM, Perniciaro C, Rogers 3rd RS. Phenytoin-induced linear IgA bullous disease. J Am Acad Dermatol. 1998;38(2 Pt 2):352–6.

    Article  CAS  PubMed  Google Scholar 

  84. Kattan KR. Thickening of the heel-pad associated with long-term Dilantin therapy. Am J Roentgenol Radium Ther Nucl Med. 1975;124:52–6.

    Article  CAS  PubMed  Google Scholar 

  85. Mancuso G, Tampieri E, Berdondini RM. Psoriasis-like eruption caused by flecainide. G Ital Dermatol Venereol. 1988;123:171–2.

    CAS  PubMed  Google Scholar 

  86. Brenner S, Cabili S, Wolf R. Psoriasiform eruption induced by quinidine. Widespread erythematous scaly plaques in an adult. Arch Dermatol. 1993;129(1331–2):1334–5.

    Google Scholar 

  87. Harwell WB. Quinidine-induced psoriasis. J Am Acad Dermatol. 1983;9:278.

    Article  CAS  PubMed  Google Scholar 

  88. Kaufmann JM, Hale EK, Ashinoff RA, Cohen DE. Cutaneous lidocaine allergy confirmed by patch testing. J Drugs Dermatol. 2002;1:192–4.

    PubMed  Google Scholar 

  89. Mackley CL, Marks Jr JG, Anderson BE. Delayed-type hypersensitivity to lidocaine. Arch Dermatol. 2003;139:343–6.

    Article  PubMed  Google Scholar 

  90. Petersen CS, Thomsen K. Pseudoporphyria. Ugeskr Laeger. 1992;154:1713–5.

    CAS  PubMed  Google Scholar 

  91. Sarkany I. Lichen planus following quinidine therapy. Br J Dermatol. 1967;79:123.

    Article  CAS  PubMed  Google Scholar 

  92. Niv Y, Shafriri P, Shlonski Z, Harush F. Erythema nodosum due to disopyramide. Harefuah. 1985;108:490.

    CAS  PubMed  Google Scholar 

  93. Quin J, Adamski M, Howlin K, Jones W, O’Neill P, Stewart G, Young A. Quinidine-induced allergic granulomatous angiitis: an unusual cause of acute renal failure. Med J Aust. 1988;148:145–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Esen Özkaya & Kurtuluş Didem Yazganoğlu

Authors
  1. Esen Özkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurtuluş Didem Yazganoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Özkaya, E., Yazganoğlu, K.D. (2014). Class I Antiarrhythmic Drugs. In: Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-6536-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6536-1_5

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6535-4

  • Online ISBN: 978-1-4471-6536-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation